MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Mascarenhas et al. analyzed the landscape of economic evaluations for medical devices in pediatrics, critically appraising their methodological rigor. The systematic literature review identified 39 economic evaluations, with a focus on high-risk therapeutic devices mostly studied in high-income countries. The analysis showed a predominant use of cost-utility analysis and considerable variation in adherence to CHEERS 2022 reporting standards. The findings highlight the need to improve reporting quality and develop methods that reflect the unique health needs of children, including outcome measures meaningful to pediatric patients and their families.

In March 2025, the French government announced a €3.9 billion increase in funding for healthcare establishments, raising the total hospital budget to €109.6 billion, a 3.8% increase from the previous year.

In March 2025, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Cucherat et al. proposed formalized methodological criteria for observational studies to serve as credible evidence for health product effectiveness, comparable to randomized controlled trials. Developed through a French expert roundtable, the framework emphasizes predefined protocols and statistical analysis plans, robust causal inference, and minimization of bias. The results offer a structured approach to support regulatory decisions and guideline development.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Lipska et al. explored the policy challenges surrounding the implementation of the EU HTA Regulation, drawing from the discussions of a high-level expert group convened in Rome. The authors proposed actionable recommendations to facilitate the effective launch of the Joint Clinical Assessment framework. Their key insights stress the need for transparent communication, stakeholder engagement, and equitable commitment from all member states to reduce access delays across Europe.

On March 21, 2025, the Federal Ministry of Health (BMG) announced that the establishment of the Transformation Fund, one of the key elements of the approved hospital reform, was formally endorsed by the Federal Council (Bundesrat) through a corresponding legal ordinance.

In March 2025, two new versions of the Nomenclature of Medical Biology Procedures (NABM 95 and 96) were released. No new tests were added. The reimbursement tariffs for several existing tests were adjusted, and one test was removed.

MTRC is pleased to announce the release of its latest White Paper: "Innovative Payment Schemes for Medical Devices". White Paper offers a summary of innovative payment schemes for medical devices that permit direct applications by the Med Tech industry, including the Innovative Devices Access Pathway (IDAP) in the UK, Forfait Innovation and Article 51 in France, and co-funded clinical studies under §137e in Germany.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Vanderwee et al. introduced a pragmatic decision-making approach for healthcare facilities with tools to select environmentally sustainable alternatives to replace single-use options. A cross-sectional multi-center survey in Belgian hospitals was performed, followed by an exploratory analysis of the sustainability of commonly used healthcare materials. The authors developed a structured assessment method, combining real-world procurement data and literature-based evaluations to inform sustainable, safe, and cost-effective material choices.

On March 4, 2025, the Member State Coordination Group on Health Technology Assessment (HTACG) published submission (‘briefing’) templates for Joint Scientific Consultations (JSC) of medical devices and in-vitro diagnostics under the EU HTAR framework. Health Technology Developers submit completed briefing templates as part of the briefing package to be considered for JSC. The JSC Outcome Document template was published as well.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Elsner et al. conducted a literature review to evaluate the economic value of cardiovascular implantable electronic devices for heart failure treatment, with a focus on the European context over the past 10 years. The review assessed the economic implications of various device therapies, including cardiac resynchronization therapy with a pacemaker (CRT-P), CRT with a defibrillator (CRT-D), implantable cardioverter-defibrillators (ICDs), pacemakers, and (semi)automated telemonitoring, using QALYs and ICERs as standardized measures of cost-effectiveness. All cardiovascular implantable electronic devices were found to fall within commonly accepted cost-effectiveness thresholds.

In February 2025, the Ministry of Health and Care Services published a National Cancer Strategy for 2025-2030. The strategy outlines five key target areas with corresponding goals and actions. The target areas comprise pioneering cancer prevention and early detection, improving patient outcomes, enhancing user-oriented cancer care, increasing survival rates and longevity, and ensuring the best possible quality of life. The actions include the expansion of national screening initiatives, the accreditation of Comprehensive Cancer Centers, digital home monitoring, precision diagnostics, and the establishment of a national healthcare innovation hub.